BioSpace News Archive

Halozyme Therapeutics, Inc. announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme’s ENHANZE® manufacturing methods that the Company provides to its current and future licensees.

Mindset Medical, Inc., a software as a medical device company, has announced the closing of a Series A financing.

AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE ®).

SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals.

Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale US study of how pneumococcal disease (PD) manifests by age group, insurance status, and sociodemographic characteristics in young children aged 0–2 years during the study period (1998–2019).

The life science group Sartorius opened its new Center of Excellence for bioanalytics in Ann Arbor, Michigan, two years after breaking ground in the Tech Loop at Research Park.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of VNS Therapy™ in treatment-resistant depression.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce the publication of a peer-reviewed study on the anticancer properties of its unconjugated AccuTOX®, one of Defence’s lead products engineered to treat established solid tumors.

Cervical spine injuries in children are relatively rare but can have serious consequences, like paralysis.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus’s commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for review medac’s April 2024 resubmission of the New Drug Application for treosulfan.